ANI Pharmaceuticals Inc - Asset Resilience Ratio
ANI Pharmaceuticals Inc (ANIP) has an Asset Resilience Ratio of 0.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ANI Pharmaceuticals Inc (ANIP) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how ANI Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ANI Pharmaceuticals Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down ANI Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ANIP long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.13 Million | 0.63% |
| Total Liquid Assets | $9.13 Million | 0.63% |
Asset Resilience Insights
- Limited Liquidity: ANI Pharmaceuticals Inc maintains only 0.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ANI Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare ANI Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
Annual Asset Resilience Ratio for ANI Pharmaceuticals Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for ANI Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.63% | $9.13 Million | $1.44 Billion | +0.14pp |
| 2024-12-31 | 0.49% | $6.31 Million | $1.28 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $904.42 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $412.14 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $322.86 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $285.26 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $263.71 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $44.50 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $38.77 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $62.38 Million | -- |
| 2008-12-31 | 17.12% | $3.03 Million | $17.68 Million | -30.91pp |
| 2007-12-31 | 48.03% | $15.01 Million | $31.24 Million | +31.06pp |
| 2006-12-31 | 16.97% | $3.80 Million | $22.37 Million | -74.85pp |
| 2005-12-31 | 91.82% | $8.79 Million | $9.57 Million | +1.51pp |
| 2004-12-31 | 90.30% | $16.10 Million | $17.83 Million | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more